Trial of Minocycline to Treat Children With Fragile X Syndrome

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single center study at the UC Davis MIND Institute in patients age 3.5-16 years of age with fragile X syndrome (FXS), funded by a National Fragile X Foundation Grant. It is a controlled trial of minocycline, an antibiotic commonly used in children for infection or for treatment of neurodegenerative disorders. We are investigating its use in FXS because it lowers matrix metalloproteinase 9 (MMP9) levels, which are high in FXS, and it also strengthens brain connections in the animal models of FXS. We hypothesize that minocycline will likely be helpful for language, behavior and/or cognition in fragile X patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Davis
• Collaborator: The National Fragile X Foundation
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Must have fragile X syndrome with molecular documentation

• Current pharmacological treatment regimen has been stable for at least 4 weeks

Exclusion Criteria:

• Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study

• subjects who are unable to take oral medication

• subjects who have been on minocycline previously

• subjects who are allergic to minocycline or tetracyclines

• subjects who are pregnant

• subjects with history of lupus or hepatic dysfunction